Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/23367
標題: Cisplatin和Go6976在乳癌細胞生長的協同抑制作用
Synergistic inhibition of breast cancer cells growth by Cisplatin and Go6976
作者: 邢華冑
Hsing, Hua-Chou
關鍵字: 順鉑;breast cancer;抗藥性;蛋白激酶抑制劑;協同作用;cisplatin;Go6973;drug resistance;protein kinase C α;inhibitor;synergistic effect
出版社: 生命科學院碩士在職專班
引用: 1.Simstein R, Burow M, Parker A, Weldon C, Beckman B. Apoptosis, Chemoresistance, and Breast Cancer : Insights From the MCF-7 Cell Model System. Exp Biol Med 2003;228:995-1003. 2.Tortora G, Caputo R, Damiano V, Bianco R, Pepe S, Bianco AR, Jiang Z, Agrawal S, Ciardiello F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci USA 1997;94:12586-91. 3.Michie AM, Nakagawa R. The link between PKCalpha regulation and cellular transformation. Immunol Lett 2005;96:155-62. 4.Lahn M, Köhler G, Sundell K, Su C, Li S, Paterson BM, Bumol TF.Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004;67:1-10. 5.Iwamoto T, Hagiwara M, Hidaka H, Isomura T, Kioussis D, Nakashima I. Accelerated proliferation and interleukin-2 production of thymocytes by stimulation of soluble anti-CD3 monoclonal antibody in transgenic mice carrying a rabbit protein kinase C alpha. J Biol Chem 1992;267:18644-8. 6.Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-15. 7.Tan M, Li P, Sun M, Yin G and Yu. D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006;25:3286-95. 8.Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Therapeu 1993;59:257-80. 9.Swannie HC, Kaye SB. Protein kinase C inhibitors [Review]. Current Oncol Reports 2002;4:37-46. 10.Benimetskaya L, Miller P, Benimetsky S, Maciaszek A, Guga P, Beaucage SL, Wilk A, Grajkowski A, Halperin AL, Stein CA. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2(G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancercells. Mol Pharmacol 2001;60:1296-307. 11.Isonishi S, Ohkawa K , Tanaka T, Howell SB. Depletion of proteinkinase C (PKC)by 12-O-tetradecanoylphorbol-13- acetate (TPA)enhances platinum drug sensitivity in human ovarian carcinomcells. Br J Cancer 2000;82:34-8. 12.Shen L, Dean NM, Glazer RI. Induction of p53-dependent, insulinlikegrowth factor-binding protein- 3-mediated apoptosis inglioblastoma multiforme cells by a protein kinase Calpha antisenseoligonucleotide. Mol Pharmacol 1999;55:396-402. 13.Ostapkowicz A, Inai K, Smith L, Kreda S, Spychala J. Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. Mol Cancer Ther. 2006;5:238-45. 14.Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep. 2003;10:1663-82. 15.國家衛生研究院,乳癌診斷與治療共識,網址http://www.nhri.org.tw/nhri_org/ca/doc/breast.pdf 16.Cancer Research UK, web site http://www.cancerhelp.org.uk/help/default.asp?page=341&template=1 17.Kostova I. Platinum Complexes as Anticancer Agents. Recent Patents on Anti-Cancer. Drug Discovery 2006;1:1-22. 18.Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep. 2004;11:559-95. 19.Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin- induced cell death always produced by apoptosis ? Mol Pharmacol 2001;59:657-63. 20.Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends in Biochem Sci 1995;20:435-9. 21.Chu, G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269 : 787-90. 22.Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marmé D, Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go6976. J Biol Chem 1993;268:9194 -7. 23.Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res 2003;63:31–5. 24.Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, Pardee AB. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Research 2003;63:290-5. 25.Baeuerle PA, Henkel T. Function and activation of NF- kappaB in the immune system. Annu Rev Immunol 1994;12:141-79. 26.Lee SI, Brown MK, Eastman A. Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochem Pharmacol. 1999;58:1713-21. 27.Hanauske AR, Sundell K, Lahn M. The role of protein kinase C-alpha (PKC- alpha) in cancer and its modulation by the novel PKC-alpha-specific inhibitor aprinocarsen. Curr Pharm Des 2004;10:1923-36. 28.Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. Protein kinase C isozymes and the regulationof diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279: 429-38. 29.Newton AC. Protein kinase C: Structural and spatial regulation by phosphorylation, cofactors,and macromolecular interactions. Chem Rev 2001;101:2352–64. 30.Lupowitz Z, Rimler A, Zisapel N. Evaluation of signal transduction pathways mediating the nuclear exclusion of the androgen receptor by melatonin .Cell Mol Life Sci 2001;58:2129-35. 31.Sampson SR, Lupowitz Z, Braiman L, Zisapel N. Role of protein kinase Calpha in melatonin signal transduction. Mol Cell Endocrinol 2006;252:82-7. 32.Garcia-Bermejo ML, Leskow FC, Fujii T, Wang Q, Blumberg PM, Ohba M, Kuroki T, Han KC, Lee J, Marquez VE, Kazanietz MG.. Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cellsby selective activation of PKC alpha. J Biol Chem 2002;277:645–55. 33.Gavrielides M, Frijhoff A, Conti C, MG K. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr Drug Targets 2004;5:431-43. 34.Iwamoto T, Hagiwara M, Hidaka H, Isomura T, Kioussis D, Nakashima I. Accelerated proliferationand interleukin-2 production of thymocytes by stimulation of soluble anti-CD3monoclonal antibody in transgenic mice carrying a rabbit protein kinase C alpha. J Biol Chem 1992;267:18644-8. 35.Mandil R, Ashkenazi E, Blass M, Kronfeld I, Kazimirsky G, Rosenthal G, Umansky F, Lorenzo PS, Blumberg PM, Brodie C. Protein kinase Calpha and protein kinase Cdelta play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001;61:4612-9. 36.Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR. Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 1993;364:249-52. 37.Buitrago CG, Pardo VG, de Boland AR, Boland R. Activation of RAF-1 through Ras and protein kinase Calpha mediates 1alpha,25(OH)2-vitamin D3 regulation of the mitogen-activated protein kinase pathway in muscle cells. J Biol Chem.2003 ;278:2199-205. 38.Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-8. 39.Soh JW, Weinstein IB. Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem 2003;278:34709-16. 40.Whelan RD, Parker PJ. Loss of protein kinase C function induces an apoptotic response. Oncogene 1998;16:1939-44. 41.Leirdal M, Sioud M. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells. Br J Cancer 1999;80:1558-64. 42.Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998;273:25436-42. 43.Ng T, Shima D, Squire A, Bastiaens PI, Gschmeissner S, Humphries MJ, Parker PJ. PKCalpha regulates beta1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J 1999;18:3909-23. 44.Ziegler WH, Tigges U, Zieseniss A, Jockusch BM. A lipid-regulated docking site on vinculin for protein kinase C. J Biol Chem 2002;277:7396-404. 45.Couchman JR, Vogt S, Lim ST, Lim Y, Oh ES, Prestwich GD, Theibert A, Lee W, Woods A. Regulation of inositol phospholipid binding and signaling through syndecan-4. J Biol Chem 2002;277:49296-303. 46.Anilkumar N, Parsons M, Monk R, Ng T, Adams JC. Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility. EMBO J 2003;22:5390-402. 47.Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res 2002;62:3538-43. 48.Morse-Gaudio M, Connolly JM, Rose DP. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol. 1998;12(6):1349-54. 49.Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer. 2000;83:782-91. 50.Carey I, Williams CL, Ways DK, Noti JD. Overexpression of protein kinase C-alpha in MCF-7 breast cancer cells results in differential regulation and expression of alphavbeta3 and alphavbeta5. Int J Oncol 1999;15:127-36. 51.Noti JD. Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 2000;17:1237–43. 52.Noti JD, Johnson AK. Integrin alpha 5 beta 1 suppresses apoptosis triggered by serum starvation but not phorbol ester in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 2001;18:195-201. 53.Williams CL, Noti JD. Reduced expression of Wnt-1 and E-cadherin, and diminished betacatenin stability in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. Int J Oncol 2001;19:1227-33. 54.Bracke ME, Van Roy FM, Mareel MM. The Ecadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol 1996;213:123-61. 55.Gupta AK, Galoforo SS, Berns CM, Martinez AA, Corry PM, Guan KL, Lee YJ: Elevated levels of ERK2 in human breast carcinoma MCF-7 cells transfected with protein kinase C alpha. Cell Prolif 1996;29:655-63. 56.Li H, Zhao L, Yang Z, Funder JW, Liu JP. Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem 1998;273:33436-42. 57.Ahmad S, Glazer RI, Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 1993;43:858-62. 58.Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21:28-34. 59.Borner C, Wyss R, Regazzi R, Eppenberger U, Fabbro D. Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: Inverse relationship to estrogen receptors. Int J Cancer1987;40:344-8. 60.Platet N, Prevostel C, Derocq D, Joubert D, Rochefort H, Garcia M. Breast cancer cell invasiveness: Correlation with protein kinase C activity and differential regulation by phorbol ester in estrogen receptor-positive and –negative cells. Int J Cancer1998;75:750-6. 61.Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res2001;7: 3156-65. 62.Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O''Brian CA, Bast RC Jr. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 2001;20:8258-69. 63.Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14. 64.Lernbecher T, Muller U, Wirth T. Distinct NF- kappaB/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 1993;365:767-70. 65.Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target. J Cell Biochem2004;92:646- 50. 66.Zhivotovsky B, Orrenius S. Defects in the apoptotic machinery of cancer cells: Role in drug resistance. Semin Cancer Biol 2003;13:125-34. 67.Pahl HL. Activators and target genes of Rel/ NF- kappaB transcription factors. Oncogene 1999;8:6853-66. 68.Garg A, Aggarwal BB. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002;16:1053-68. 69.Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase 8 activation. Science 1998;281:1680-3. 70.Das KC, White CW. Activation of NF-kappaB by antineoplastic agents: role of protein kinase C. J Biol Chem 1997;272:14914-20. 71.Hwang S, Ding A. Activation of NF-kappaB in murine macrophages by taxol. Cancer Biochem Biophys 1995;14:265-72. 72.Huang TT, Wuerzberger-Davis SM, Seufzer BJ, Shumway SD, Kurama T, Boothman DA, Miyamoto S. NF-kappaB activation by camptothecin: a linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem 2000;275:9501-9. 73.Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory disease. J Clin Invest 2001;107:7-11. 74.Nakshatri H, Goulet RJ Jr. NF-kappaB and Breast Cancer. Curr Probl Cancer 2002;26:282-309. 75.Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9. 76.Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002;277:26553-64. 77.Eastman A, Kohn EA, Brown MK, Rathman J, Livingstone M, Blank DH, Gribble GW. A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Mol Cancer Ther 2002;1:1067-78. 78.Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-kappa B sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog. 2005;44:51-9. 79.Gonindard C, Bergonzi C, Denier C, Sergheraert C, Klaebe A, Chavant L, Hollande E. Synthetic hispidin, a PKC inhibitor, is more cytotoxic toward cancer cells than normal cells in vitro. Cell Biol Toxicol. 1997;13:141-53. 80.Aaltonen V, Koivunen J, Laato M, Peltonen J. mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.Cancer Lett 2007;253:97-107. 81.Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79. 82.Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr. Constitutive activation of NF-KappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39. 83.Bhat-Nakshatri P, Newton TR, Goulet R Jr, Nakshatri H. NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer-derived interleukin 1alpha. Proc Natl Acad Sci U S A 1998;95:6971-6. 84.Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002 25;108:153-64. 85.Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression, Cancer Lett 2006;235:1-10. 86.Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res 2004;64:5693-701. 87.Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression inestrogen-receptor negative breast cancer cells. Proc. Natl Acad Sci USA 2000;97:8542-7. 88.Monks NR, Pardee AB. Targeting the NF-kappaB pathway in cancer cells estrogen receptor negative MDA-MB-231 breast using small inhibitory RNAs. J Cell Biochem 2006;98:221-33. 89.Zlatanova J, Yaneva J, Leuba SH. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 1998;12:791-9. 90.Zamble DB, Lippard SJ, Cisplatin and DNA repair in cancer therapy. http://bioweb.wku.edu/courses/Biol588/Bishopl.html
摘要: 
Cisplatin是已知有效抗腫瘤藥劑之一,在臨床上廣泛運用在許多不同固體瘤的治療,它可以造成細胞DNA損傷,影響細胞存活甚至造成不可逆的凋亡程式,但以cisplatin為基礎的化學治療其療效受限於抗藥性的產生。已知蛋白激酶Cα與癌細胞的惡化轉型、生長、凋亡、轉移和活化有關連,研究報告顯示蛋白激酶Cα在癌症治療上是一個 具有潛力的標的蛋白。而Go6976是蛋白激酶Cα/β和檢查點激酶Chk1/Chk2的抑制劑,它會增進腫瘤細胞對毒性藥劑的敏感度。本研究使用兩種不同表現型的乳癌細胞株,MCF-7 (ER+, wild type p53) 和 MDA-MB-231 (ER-, p53 mutant),分別以cisplatin和Go6976組合處理以觀察對此兩種細胞株的細胞生長是否有抑制情形,結果顯示這兩種藥物的組合在MDA-MB-231細胞株產生明顯的協同抑制效果,而在MCF-7細胞株則無,這種不同作用機制的藥物協同作用,將可降低化療使用的藥物濃度,避免傷害正常細胞,減低藥物引起的副作用。
URI: http://hdl.handle.net/11455/23367
其他識別: U0005-1508200823274300
Appears in Collections:生命科學系所

Show full item record
 

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.